Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.41 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | GGT1 | P19440 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19360085 | 0.85 | EPHX2 (0.42) | FOLH1CA2CA4NAALAD2RIMKLA | |
| SCHEMBL22001982 | 0.83 | TGFBR1 (0.50) | FOLH1CA2MMENAALAD2RIMKLA | |
| SCHEMBL2742767 | 0.82 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19788058 | 0.82 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14177314 | 0.80 | FOLH1 (0.60) | FOLH1CA2CA4MMENAALAD2 | |
| SCHEMBL18538622 | 0.79 | FPR2 (0.47) | FOLH1NAALAD2RIMKLAMAPTGGT1 | |
| SCHEMBL21915797 | 0.79 | CA2 (0.47) | FOLH1CA2CA4MMENAALAD2 | |
| SCHEMBL7091886 | 0.76 | GGT1 (0.56) | FOLH1CA2CA4MMEGGT1 | |
| SCHEMBL692576 | 0.76 | GGT1 (0.56) | FOLH1CA2CA4MMEGGT1 | |
| SCHEMBL381772 | 0.76 | GGT1 (0.56) | FOLH1CA2CA4MMEGGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267717-A1 | Novel method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267717-A1 | Novel method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer | FGB, F13B, FAP | FOLH1 7/4885CA2 1558/4885CA4 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.